Literature DB >> 33651355

PCA3 in Prostate Cancer.

Roberta Gunelli1, Eugenia Fragalà1, Massimo Fiori2.   

Abstract

Prostate cancer antigen 3 (PCA3) is a urinary biomarker for prostate cancer and has demonstrated a good specificity and sensitivity representing a minimally invasive test.PCA3 assay could be useful in combination with PSA to suggest an eventual rebiopsy in men who have had one or more previous negative prostate biopsies.Combination of multiple tumor biomarkers will be the trend in the near future to achieve the goal of evaluate the aggressiveness of cancer and at the same time reducing the number of unnecessary biopsies.

Entities:  

Keywords:  Biomarker; DD3; PCA3; Prostate Biopsy; Prostate Cancer

Mesh：

Substances：

Year:  2021        PMID： 33651355     DOI： 10.1007/978-1-0716-1354-2_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  6 in total

Review 1.  Function of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score.

Authors:  Yue Wang; Xiao-Jun Liu; Xu-Dong Yao
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

2.  How is the association between urinary prostate cancer antigen 3 (PCA3) levels and Gleason scores in patients suspicious of prostate cancer?

Authors:  Sasan Gilani; Mina Shakery; Pouria Shoureshi; Hojjat Salimi; Hadi Maleki; Ali Alavi; Farinaz Khodadadi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-12-15

Review 3.  A critical appraisal of biomarkers in prostate cancer.

Authors:  Vikram M Narayan
Journal:  World J Urol       Date:  2019-04-16       Impact factor: 4.226

4.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

Authors:  M J Bussemakers; A van Bokhoven; G W Verhaegh; F P Smit; H F Karthaus; J A Schalken; F M Debruyne; N Ru; W B Isaacs
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

5.  Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis.

Authors:  Sandra Viviana Muñoz Rodríguez; Herney Andrés García-Perdomo
Journal:  Can Urol Assoc J       Date:  2019-11-29       Impact factor: 1.862

6.  New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression.

Authors:  Raymond A Clarke; Zhongming Zhao; An-Yuan Guo; Kathrein Roper; Linda Teng; Zhi-Ming Fang; Hema Samaratunga; Martin F Lavin; Robert A Gardiner
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240
  6 in total
  3 in total

1.  [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].

Authors:  M Yang; X Zhu; Y Shen; Q He; Y Qin; Y Shao; L Yuan; H Ye
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-08-20

2.  Correlation of NTRK1 Downregulation with Low Levels of Tumor-Infiltrating Immune Cells and Poor Prognosis of Prostate Cancer Revealed by Gene Network Analysis.

Authors:  Arash Bagherabadi; Amirreza Hooshmand; Nooshin Shekari; Prithvi Singh; Samaneh Zolghadri; Agata Stanek; Ravins Dohare
Journal:  Genes (Basel)       Date:  2022-05-08       Impact factor: 4.141

Review 3.  Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma.

Authors:  José A Peña-Flores; Mercedes Bermúdez; Rosalío Ramos-Payán; Carlos E Villegas-Mercado; Uriel Soto-Barreras; Daniela Muela-Campos; Alexis Álvarez-Ramírez; Brenda Pérez-Aguirre; Ana D Larrinua-Pacheco; César López-Camarillo; Jorge A López-Gutiérrez; Julio Garnica-Palazuelos; Marvin E Estrada-Macías; Juan L Cota-Quintero; Andrés A Barraza-Gómez
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.